On the eve of ACTRIMS Forum 2019, Dr. Jeffrey Cohen explains the professional society’s unique mission and how it aims to keep paralleling the fast-evolving MS subspecialty it serves.
The first generic forms of disease-modifying therapies for MS are here, with more expected soon. Dr. Jeffrey Cohen reflects on how clinicians might best approach them.
Dr. Jeffrey Cohen outlines the primary changes and unresolved issues in this revision of the diagnostic standard in multiple sclerosis — the first in seven years.
Stem cells show potential as disease-modifying and restorative therapy in a range of nervous system disorders, but they’re far from ready for prime time. An expert outlines the reasons why and the road ahead.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The new-generation S1P receptor modulator shows impressive effects on relapse rate and MRI lesion activity with no significant safety concerns. The trial’s lead investigator looks ahead to what’s next.
The new GATE trial shows that generic glatiramer acetate matches the branded version in every way. The study’s lead author shares perspectives via a Medscape-Cleveland Clinic editorial collaboration.
Generic versions of costly multiple sclerosis therapies have been few and far between, in part because of these compounds’ complexity. That may be changing with results of the international GATE trial.
Phase 1 study of stem cell therapy for multiple sclerosis finds no safety issues or signs of disease activation — plus “enticing hints” of benefits to be explored in phase 2 testing.